Gaining a Pulse on Formulation and Drug Delivery Challenges and Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gaining a Pulse on Formulation and Drug Delivery Challenges and Technologies
A recent survey examines the industry's views on the chief challenges and technologies in drug delivery and formulation development.


Pharmaceutical Technology
Volume 36, Issue 4

Seeking solutions

In addressing problems of bioavailability and solubility, "there are two dimensions to which to address solubility of poorly soluble drugs, the drug substance and drug product," says Kurt Nielsen, PhD and senior vice-president, innovation and growth with Catalent Pharma Solutions, in commenting on the survey results. With respect to the drug substance, he points to various solutions, such as optimizing the salt form or solid-state form (i.e., polymorph or co-crystal). Slight modifications to the drug substance also can be made to improve solubility, such as converting the drug to a prodrug, or by reducing the particle size of the drug substance, explains Nielsen.

With respect to the drug product, Nielsen says that various methods can improve solubility, ranging from straightforward strategies, such as solubilizing agents (e.g., surfactants and polymers) to more complex solutions where site-specific drug release is required to address such issues as poor stability of the drug in the stomach or pre-systematic metabolism in certain locations in the gastrointestinal tract. As with the drug substance, particle engineering can be used to not only optimize solubility but also to modify or control the release of the drug, he adds. In sum, these strategies seek to address the key aspects of solubility, permeability, and site of absorption.

On a dosage form level, various approaches may be used. "Liquid-based dosage forms, such as softgels, dispersion-based dosage forms through hot-melt or spray-dried dispersions, and drug layering and coating can be used to improve solubility and bioavailability of oral dosage forms," says Nielsen. If bioavailability is still a problem, other routes of administration, such as transdermal, buccal, and sublingual drug delivery can be considered.

Reference

1. Catalent–Pharmaceutical Technology Landscape Drug Delivery Survey (December 2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here